Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Mais filtros











Base de dados
Intervalo de ano de publicação
1.
J Pediatr ; 163(6): 1605-1611.e3, 2013 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-23998516

RESUMO

OBJECTIVE: To estimate the effects of prenatal vitamin D supplementation on infant growth in Dhaka, Bangladesh. STUDY DESIGN: Longitudinal follow-up of infants born at term or late preterm (≥34 weeks) to participants in a randomized double-blind trial of maternal third-trimester vitamin D3 (35 000 IU/wk; vitamin D ) vs placebo. Anthropometry was performed at birth, 1, 2, 4, 6, 9, and 12 months of age. The primary analysis (n = 145 overall; n = 134 at 1 year) was a comparison of mean length-for-age z-score (LAZ) based on World Health Organization standards. RESULTS: LAZ was similar between groups at birth, but 0.44 (95% CI, 0.06-0.82) higher in vitamin D vs placebo at 1 year, corresponding to a sex-adjusted increase of 1.1 cm (95% CI, 0.06-2.0). Mean change in LAZ from birth to 1 month was significantly greater in vitamin D (0.53 per month) vs placebo (0.19 per month; P = .004); but there was no significant divergence thereafter. In longitudinal (repeated-measures) analysis, average LAZ during infancy was 0.41 higher in vitamin D vs placebo (95% CI, 0.11-0.71, P = .01). Stunting was less common in vitamin D (17% of infants were ever stunted) vs placebo (31%; P = .049). Other anthropometric indices were similar between groups. CONCLUSIONS: Maternal vitamin D3 supplementation (35 000 IU/wk) during the third trimester of pregnancy enhanced early postnatal linear growth in a cohort of infants in Bangladesh.


Assuntos
Desenvolvimento Infantil , Colecalciferol/uso terapêutico , Suplementos Nutricionais , Crescimento , Complicações na Gravidez/tratamento farmacológico , Deficiência de Vitamina D/tratamento farmacológico , Vitaminas/uso terapêutico , Bangladesh , Método Duplo-Cego , Feminino , Seguimentos , Humanos , Lactente , Recém-Nascido , Estudos Longitudinais , Masculino , Gravidez , Terceiro Trimestre da Gravidez
3.
J Infect Dis ; 190(5): 920-7, 2004 Sep 01.
Artigo em Inglês | MEDLINE | ID: mdl-15295697

RESUMO

BACKGROUND: Polymorphisms in the gene that encodes the vitamin D receptor (VDR) may influence the host response to Mycobacterium tuberculosis infection. METHODS: In a Peruvian community with a high incidence of tuberculosis (TB), VDR TaqI and FokI polymorphisms were compared among 103 patients with pulmonary TB and 206 matched healthy control subjects. Associations of VDR polymorphisms with treatment outcome were analyzed among 78 patients undergoing treatment of pulmonary TB. RESULTS: Sputum mycobacterial culture and auramine stain conversions were significantly faster among participants with the FokI FF genotype, compared with participants with the non-FF genotypes. Sputum culture conversion was faster among participants with the TaqI Tt genotype, compared with those with the TT genotype. Increased probability of culture conversion during TB treatment was independently associated with the TaqI Tt genotype (age- and sex-adjusted relative risk, 4.28; 95% confidence interval, 1.88-9.75; P = .001). VDR polymorphisms were not significantly associated with susceptibility to TB in the case-control study. CONCLUSIONS: VDR gene polymorphisms are associated with the time to sputum culture and auramine stain conversion during TB treatment. To our knowledge, the present study is the first report of a specific host gene influence on the outcome of TB treatment. These findings demonstrate the potential clinical relevance of immunomodulatory functions of vitamin D metabolites acting via the VDR in the host response against pulmonary TB.


Assuntos
Antituberculosos/uso terapêutico , Predisposição Genética para Doença , Mycobacterium tuberculosis/efeitos dos fármacos , Polimorfismo Genético , Receptores de Calcitriol/genética , Tuberculose Pulmonar/genética , Adolescente , Adulto , Estudos de Casos e Controles , Desoxirribonucleases de Sítio Específico do Tipo II , Humanos , Incidência , Pessoa de Meia-Idade , Peru , Estudos Prospectivos , Resultado do Tratamento , Tuberculose Pulmonar/tratamento farmacológico , Tuberculose Pulmonar/epidemiologia
4.
J Infect Dis ; 188(9): 1263-75, 2003 Nov 01.
Artigo em Inglês | MEDLINE | ID: mdl-14593583

RESUMO

To characterize posttreatment recurrence of Helicobacter pylori in Peru, 192 adults with H. pylori-positive gastric biopsy specimens were monitored by (14)C-Urea breath test, after eradication of H. pylori by use of amoxicillin, clarithromycin, and omeprazole. The cumulative risk of recurrence at 18 months was 30.3% (95% confidence interval, 21.4%-39.3%). Randomly amplified polymorphic DNA patterns and DNA sequence data established that, among 28 pairs of H. pylori isolates from pretreatment and recurrent infections, 6 (21%) were genetically similar, suggesting recrudescence of the previous infection, and 22 (79%) were different, suggesting reinfection with a new strain that differed from that involved in the initial infection. Eating mainly outside of the home was a risk factor for infection with a new strain (adjusted relative risk [RR], 5.07), whereas older age was a protective factor (adjusted RR, 0.20). Although an increase in the anti-H. pylori IgG antibody titer corresponded to recurrence, pretreatment and recurrent infections were similar with respect to quantitative culture colony counts and histologic characteristics, suggesting that neither prior eradication nor the memory immune response measurably alters the risk or burden of recurrent infection. Although eradication with antibiotics was successful, the high rate of reinfection suggests that treatment is unlikely to have a lasting public health effect in this setting.


Assuntos
Quimioterapia Combinada/uso terapêutico , Infecções por Helicobacter/tratamento farmacológico , Helicobacter pylori/crescimento & desenvolvimento , Adolescente , Adulto , Amoxicilina/administração & dosagem , Antiulcerosos/uso terapêutico , Biópsia , Testes Respiratórios , Claritromicina/administração & dosagem , Estudos de Coortes , DNA Bacteriano/química , DNA Bacteriano/genética , Feminino , Infecções por Helicobacter/epidemiologia , Infecções por Helicobacter/microbiologia , Infecções por Helicobacter/patologia , Helicobacter pylori/genética , Helicobacter pylori/metabolismo , Humanos , Masculino , Omeprazol/administração & dosagem , Peru/epidemiologia , Pobreza , Técnica de Amplificação ao Acaso de DNA Polimórfico , Recidiva , População Urbana
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA